Modality
mRNA
MOA
KRASG12Di
Target
GLP-1R
Pathway
Ferroptosis
MelanomaHeart Failure
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
May 2018
→ May 2027
Phase 1Current
NCT04597803
2,064 pts·Heart Failure
2018-05→2027-05·Recruiting
2,064 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-05-061.1y awayPh2 Data· Heart Failure
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P1/2
Recruit…
Catalysts
Ph2 Data
2027-05-06 · 1.1y away
Heart Failure
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04597803 | Phase 1/2 | Heart Failure | Recruiting | 2064 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Ivotuximab | GSK | NDA/BLA | GIP-R |